| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8441790 | European Journal of Cancer | 2015 | 9 Pages |
Abstract
Despite slightly more adverse events and dose reductions, neoCTx is feasible in elderly patients with EGC. Elderly patients achieve comparable survival outcomes compared with their younger counterparts.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Lorenzen Sylvie, Spoerl Silvia, Al-Batran Salah-Eddin, Feith Markus, Lordick Florian, Thuss-Patience Peter, Haller Bernhard, Angele Martin, Novotny Alexander,